Entity

Time filter

Source Type


Liu X.,Southern Medical University | Wang W.,Guangzhou RiboBio Co. | Samarsky D.,Guangzhou RiboBio Co. | Liu L.,Southern Medical University | And 16 more authors.
Nucleic Acids Research | Year: 2014

RNAi technology is taking strong position among the key therapeutic modalities, with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development. To further explore potentials of RNAi technology as therapeutics, we engineered and tested VEGFR2 siRNA molecules specifically targeted to tumors through covalently conjugated cyclo(Arg-Gly-Asp-d-Phe-Lys[PEG-MAL]) (cRGD) peptide, known to bind αvβ3 integrin receptors. cRGD-siRNAs were demonstrated to specifically enter and silence targeted genes in cultured αvβ3 positive human cells (HUVEC). Microinjection of zebrafish blastocysts with VEGFR2 cRGD-siRNA resulted in specific inhibition of blood vessel growth. In tumor-bearing mice, intravenously injected cRGD-siRNA molecules generated no innate immune response and bio-distributed to tumor tissues. Continuous systemic delivery of two different VEGFR2 cRGD-siRNAs resulted in down-regulation of corresponding mRNA (55 and 45%) and protein (65 and 45%) in tumors, as well as in overall reduction of tumor volume (90 and 70%). These findings demonstrate strong potential of cRGD-siRNA molecules as anti-tumor therapy. © 2014 The Author(s). Source


Jiang G.-X.,Guangdong Shuanglin Bio pharmaceutical Co. | Zhang W.,Guangdong Shuanglin Bio pharmaceutical Co. | Hong H.-W.,Guangdong Shuanglin Bio pharmaceutical Co. | Lv Y.-N.,Guangdong Shuanglin Bio pharmaceutical Co.
Chinese Journal of Biologicals | Year: 2015

Human coagulation factor YIII (F III) is a glycoprotein with the function of clotting in the blood, which serves as a co-factor for factor IXa (FIXa) in the activation of factor X (FX) to factor Xa (FXa) during the complex blood clotting cascade. FVIII is unstable whether in vitro or in vivo because of its complex structure. This article reviews the stability of FVIII in the whole manufacture progress including collection of material plasma, purification, package, storage and clinic infusion. Source


Jiang G.-X.,Guangdong Shuanglin Bio pharmaceutical Co. | Zhang W.,Guangdong Shuanglin Bio pharmaceutical Co. | Zhu G.-Z.,Guangdong Shuanglin Bio pharmaceutical Co. | Lv Y.-N.,Guangdong Shuanglin Bio pharmaceutical Co.
Chinese Journal of Biologicals | Year: 2015

Objective: To investigate the relationship between sodium chloride content and crystalline form of freeze-dried human coagulation factor VI (FV1) and provide a basis for the quality control of FVIII. Methods: Highly purified FV1 was prepared by anion-exchange chromatography, then added with sodium chloride to low (40 mmol/L), moderate (80 mmol/L) and high (160 mmol/L) concentrations respectively and lyophilized in vacuum, using the freeze-dried FVIII containing 160 mmol/L sodium chloride and 100 mmol/L glycine as control. The appearance of freeze-dried FVE was examined visually, while the crystalline form was observed by scanning electron microscopy (SEM), the thermodynamic property was evaluated by differential scanning calorimeter (DSC), and the activity, moisture content and reconstitution time according to the requirements in Chinese Pharmacopoeia (Volume IH, 2010 edition). Results: Along with the increasing sodium chloride concentration, the appearance of FVIII changed from loose hole-net structure to dense lamellar structure, the eutectic point was lowered, and clotting activity decreased, and time for reconstitution increased, and the moisture content increased. However, the appearance of FVIII using glycine as a stabilizer showed a loose hole-net structure, of which the eutectic point and clotting activity increased, and the time for reconstitution and moisture content decreased. Conclusion: The crystalline form of lyophilized FVIII was distinctly influenced by sodium chloride content. The sodium chloride content should be adjusted while the stabilizer should be added during formulation of FVH solution to control the crystalline form of freeze-dried FVIII. Source

Discover hidden collaborations